Last reviewed · How we verify
Intravitreal injection of pegaptanib sodium
At a glance
| Generic name | Intravitreal injection of pegaptanib sodium |
|---|---|
| Also known as | Macugen 0.3mg |
| Sponsor | University of Oxford |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Pegaptanib Therapy in Non-Infectious Uveitic Cystoid Macular Edema (NA)
- Extension Study to Gather Data on Effect of Macugen on the Corneal Endothelium (PHASE4)
- A Study On The Efficacy Of Macugen Injections In Patients With Neovascular Age-Related Macular Degeneration In Real Life.
- A Multi-Center Trial To Evaluate The Safety And Efficacy Of Pegaptanib Sodium(Macugen) Injected Into The Eye Every 6 Weeks For Up To 2 Years For Macular Swelling Associated With Diabetes, With An Open-Label Macugen Year Extension. (PHASE2, PHASE3)
- Cohort Study of the Clinical Course of Macular Diseases in Kagawa (PHASE4)
- Cohort Study of the Clinical Course of Macular Diseases in Japanese
- A Safety and Efficacy Study Comparing the Combination Treatments of Verteporfin Therapy Plus One of Two Different Doses of Intravitreal Triamcinolone Acetonide and the Verteporfin Therapy Plus Intravitreal Pegaptanib (PHASE3)
- Intravitreal Pegaptanib in Treatment of Choroidal Neovascularisation Secondary to Pathologic Myopia (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: